Table 1.
Baseline socio-demographic and clinical characteristics of 58 larynx-hypopharynx cancer patients, according to regular antiplatelets use
| Non-Antiplatelets users | Antiplatelets users | Fisher exact test | |||
|---|---|---|---|---|---|
| N | (%) | n | (%) | ||
| Sex | |||||
| Men | 34 | (89.5) | 16 | (80.0) | p = 0.43 |
| Women | 4 | (10.5) | 4 | (20.0) | |
| Age (years) | |||||
| <65 | 28 | (73.7) | 5 | (25.0) | p <0.01 |
| ≥65 | 10 | (26.3) | 15 | (75.0) | |
| Tobacco smoking | |||||
| Never | 5 | (13.2) | 4 | (20.0) | p = 0.70 |
| Ever | 33 | (86.8) | 16 | (80.0) | |
| T status | |||||
| T2–T3 | 27 | (71.0) | 20 | (100.0) | p = 0.01 |
| T4 | 11 | (29.0) | 0 | (0.0) | |
| N status | |||||
| N0 | 11 | (29.0) | 8 | (40.0) | p = 0.56 |
| N1–N3 | 27 | (71.0) | 12 | (60.0) | |
| Stage | |||||
| III | 13 | (34.2) | 15 | (75.0) | p <0.01 |
| IV | 25 | (65.8) | 5 | (25.0) | |
| Platelet count at radiotherapy beginning (cells/μL) | |||||
| <250.000 | 19 | (51.3) | 11 | (57.9) | p = 0.78 |
| ≥250.000 | 18 | (48.7) | 8 | (42.1) | |
| Locoregional recurrence | |||||
| No | 17 | (44.7) | 16 | (80.0) | p = 0.01 |
| Yes | 21 | (55.3) | 4 | (20.0) | |